

ABBREVIATED CURRICULUM VITAE

Leigh Ann Burns Naas, PhD DABT ATS ERT

37. Ladics, G.S., Chapin, R.E., Hastings, K.L., Hippie, M.P., Makris, S.L., Sheet, L.P., Woolhiser, M.R., and Burns-Naas, L.A. Developmental toxicology evaluations – issues with including

- hyperplasia induced by the RAF inhibitor PF-04880594 is attenuated by a clinically well-tolerated dose of the MEK inhibitor PD-0325901 Molecular Cancer Therapeutics 1(10):1-10, 2012.
49. McKarns, S.C., Miller, P.G., Palmer, R.K., Pfau, J.C., Raman, P., Regal, J.F., Rodgers, K.E., Schondelmeyer, R.S., Zhang, X., Cohen, M.D., Dean, J.H., Franko, J., Kerkvliet, N.I., Laiosa, M.D., Lawrence, B.P., Luebke, R.W., Luster, M.I., BonhB., and Burns-Naas, L.A. Immunotoxicology: